{
    "code": "60001022",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60001022",
    "time": "2019-09-20 03:04:33",
    "許可證字號": "衛部菌疫輸字第001022號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "110\/09\/29",
    "發證日期": "105\/09\/29",
    "許可證種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA06000102207",
    "中文品名": "莫須瘤皮下注射劑",
    "英文品名": "MabThera solution for subcutaneous injection",
    "適應症": "1.何杰金氏淋巴瘤\r\n(1)用於復發或對化學療法有抗性之低惡度B-細胞非何杰金氏淋巴瘤，且對誘導療法產生療效反應後之維持治療。\r\n(2)併用CVP或CHOP化學療法用於未經治療之和緩性(組織型態為濾泡型) B細胞非何杰金氏淋巴瘤的患者。\r\n(3)併用CHOP或其他化學療法用於CD20抗原陽性之瀰漫性大型B細胞非何杰金氏淋巴瘤。\r\n(4)用於做為濾泡性淋巴瘤患者對誘導療法產生反應之後的維持治療用藥。\r\n2.慢性淋巴球性白血病\r\n(1)莫須瘤(MabThera)適用於與fludarabine及cyclophosphamide併用，做為CD20陽性慢性淋巴球性白血病(CLL)患者的第一線用藥。\r\n(2)莫須瘤(MabThera)適用於與化學療法併用，做為復發\/頑固性的CD20陽性慢性淋巴球性白血病患者的治療用藥。",
    "劑型": "220皮下注射劑",
    "包裝": "100支以下盒裝 1400毫克\/11.7毫升玻璃小瓶裝 1600毫克\/13.4毫升玻璃小瓶裝",
    "": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "-->\r\n                    \r\n                        \r\n                            標籤、仿單及包裝加註": [
        ""
    ],
    "藥品類別": "05限由醫師使用",
    "主成分略述": "Rituximab",
    "主製造廠": {
        "申請商名稱": "1901701100  羅氏大藥廠股份有限公司",
        "申請商地址": "台北市信義區松仁路100號40樓、40樓之1、41樓之1",
        "主製造廠": "",
        "製造廠名稱": "FCH0257000  F. HOFFMANN-LA ROCHE LTD."
    },
    "CCC號列": "30021500005 免疫產品，具有劑量或零售包裝式樣者Immunological products, put up in measured doses or in forms or packings for retail sale",
    "藥理治療分類": "",
    "次製造廠": [
        {
            "製造廠名稱": "FUS0767000  GENENTECH, INC.",
            "製造廠廠址": "1000 NEW HORIZONS WAY, VACAVILLE, CA 95688, USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "原料藥製造廠"
        }
    ],
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013002400",
            "成分名稱": "Rituximab",
            "含量描述": "",
            "含量": "120.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "Mabthera SC_CDS 28.0_0519-MSC-01 (450x500mm)-108-06-19(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001022&Seq=003&Type=9"
        },
        {
            "title": "100010220001-106-08-18.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001022&Seq=002&Type=9"
        },
        {
            "title": "Mabthera SC_1600 mg_001022-2-CTN-02-108-07-05(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001022&Seq=011&Type=8"
        },
        {
            "title": "Mabthera SC_1400 mg_001022-1-CTN-04-out-108-04-18(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001022&Seq=010&Type=8"
        },
        {
            "title": "Mabthera SC 1600mg_SUC_001022-2-CTN-01-107-03-01(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001022&Seq=009&Type=8"
        },
        {
            "title": "Mabthera SC 1400mg_SUC_001022-1-CTN-03-107-03-01(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001022&Seq=008&Type=8"
        },
        {
            "title": "1.6.2 proposed STK-106-07-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001022&Seq=007&Type=8"
        },
        {
            "title": "1.6.2 proposed LAB-106-07-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001022&Seq=006&Type=8"
        },
        {
            "title": "1.6.2 proposed FB-106-07-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001022&Seq=005&Type=8"
        },
        {
            "title": "10182301_20170710-106-07-10(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001022&Seq=004&Type=8"
        },
        {
            "title": "100010220003_sticker-105-11-28.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001022&Seq=003&Type=8"
        }
    ]
}